deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03906136

AScalate: Treat-to-target in Axial Spondyloarthritis (AScalate)

A Randomized, Open Label Multicenter Trial to Investigate the Efficacy of a Treat-to-target (T2T) Treatment Strategy With Secukinumab (AIN457) as a First-line Biologic Compared to a Standard-of-care (SOC) Treatment Over 36 Weeks in Patients With Active Axial Spondyloarthritis (axSpA)

Sponsor: Novartis Pharmaceuticals

Updated 17 times since 2019 Last updated: Apr 25, 2025 Started: Jun 4, 2019 Primary completion: Feb 4, 2022 Completion: Sep 22, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Axial Spondyloarthritis, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 17 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Feb 2023 · 12 months · monthly snapshot~Feb 2023 – ~Aug 2023 · 6 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. May 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — May 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE3

Show 12 earlier versions
  1. Feb 2023 — Aug 2023 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  2. Feb 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Jan 2022 — Feb 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  4. Sep 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  5. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  6. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  7. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  8. Apr 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  9. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

  10. Sep 2019 — Mar 2020 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  11. Jul 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE3

  12. May 2019 — Jul 2019 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .